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Pere Barba,1 Jose Luis Pin˜ana,1 David Valcarcel,1 Luis Querol,2 Rodrigo Martino,1
Anna Sureda,1 Javier Briones,1 Julio Delgado,1 Salut Brunet,1 Jorge Sierra1Neurological complications (NC) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are
common and life-threatening in most cases. They may involve either the central (CNS) or peripheral nervous
system (PNS). The aim of this study was to describe incidence and characteristics of NC after reduced-inten-
sity conditioning allo-HSCT (allo-RIC), an unexplored setting. For this purpose, we reviewed 191 consecutive
patients who underwent this procedure at our institution between January 1999 and December 2006. The
median follow-up for survivors was 48 months (3-98 months). RIC included fludarabine (Flu) 150 mg/m2 in
combinationwith busulfan (Bu) 8-10 mg/kg (n5 61), melphalan (Mel) 70-140 mg/m2 (n5 119), cyclophospha-
mide (Cy) 120 mg/kg (n5 7), or low-dose total body irradiation (TBI) 2 Gy (n5 4). Graft-versus-host disease
(GVHD) prophylaxis consisted of cyclosporine A (CsA) in combinationwithmethotrexate (MTX; n5 134) or
mycophenolate mofetil (MMF; n5 52). Twenty-seven patients (14%) developed a total of 31 NC (23 CNS and
8 PNS) for a 4-year cumulative incidence of 16% (95% confidence interval [CI] 11-23). CNS complications in-
cluded nonfocal encephalopathies in 11 patients, meningoencephalitis in 5 patients, and stroke or hemorrhage
in 4. PNS complications consisted of 5 cases of mononeuropathies and 3 cases of polyneuropathies. Drug-re-
lated toxicity was responsible for 10 of the 31 events (32%) (8 caused by CsA). Interestingly, 14 of the 23 CNS
events (61%) and only 1 of the 8 PNS complications (13%) appeared before day 1100 (P5.01). Overall, pa-
tients presentingNC showed a trend for higher 1-year nonrelapsemortality (NRM) (37% versus 20%, P5.08).
In patients with CNS involvement, 1-year NRM was significantly worse (42% versus 20%, P5.02). CNS NC
also had a negative impact on 4-year overall survival (OS; 33% versus 45%, P5.05). In conclusion, our study
showed that NC are observed after allo-RIC and have diverse features. NC affecting the CNS have earlier
onset and worse outcome than those involving the PNS.
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6/j.bbmt.2009.07.013a consolidated treatment for several hematologic and
nonhematologic diseases. Because of its toxicity, this
procedure is usually restricted to young (\55 years)
and medically fit patients. For those who are ineligible
for high-dose therapy, reduced-intensity conditioning
regimens (allo-RIC) have been developed. Although
nonrelapse mortality (NRM) is lower in patients
receiving allo-RIC than in those treated with MA con-
ditioning [1], graft-versus-host disease (GVHD), in-
fections, and organ toxicities (including lung, kidney,
gastrointestinal [GI], liver, and neurologic toxicities)
limit the success of this new transplantation approach.
To improve the outcome, better understanding and
prevention of the complications of the procedure are
necessary.
Despite neurologic complications (NC) after allo-
HSCT representing a major cause of morbidity and1439
1440 Biol Blood Marrow Transplant 15:1439-1446, 2009P. Barba et al.mortality, they have not been well characterized to
date. Most studies about NC were focused on hetero-
geneous groups of patients, including autologous and
allogeneic transplants, RIC and conventional prepara-
tive regimens, and different stem cell sources [2-4].
The characteristics of NC in a specific setting (ie,
allo-RIC) are unclear, because very few studies were
exclusively conducted in this setting [5,6]. Further-
more, data on long-term NC developing beyond 1
year are limited because of the relatively short fol-
low-up in most studies [2-5,7]. In the first year after
transplantation, the incidence of central nervous sys-
tem (CNS) complications ranged from 8-56% [2-4].
Postransplant peripheral nervous system (PNS) com-
plications were less frequent, with reported incidences
of\5% [5,7].
In the vast majority of studies, metabolic and drug-
related toxicities were the most common causes of NC
after transplantation. More specifically, toxicity from
radiation or drugs (mainly fludarabine [Flu], busulfan
[Bu], and calcineurin inhibitors), infections resulting
from immunodeficiency and tissue barrier break-
through, bleeding because of thrombocytopenia, ste-
roid treatment for GVHD, and disease relapse were
reported as etiologies and/or risk factors of NC after
allo-HSCT [3,5,6,8]. Main neurologic symptoms
were seizures and impaired consciousness [2,8-10]. Be-
cause of the diversity of causes, clinical features, and
nervous systems affected (CNS or PNS) the study of
NC remains a challenge.
In view of these limitations, we considered it inter-
esting to investigate the incidence, characteristics, and
etiologies of NC after allo-RIC. As an additional
novelty, the prolonged follow-up of the study
presented here allowed differentiating between early
and late CNS and PNS complications.PATIENTS AND METHODS
Patients
The study included all 191 consecutive patients
who underwent allo-RIC in our institution between
January 1999 and December 2006. RIC was chosen
instead of MA conditioning in view of age (older
than 50 years, n5 121), severe comorbidities
(n5 11), or heavy pretreatment (n5 59), as described
elsewhere [11,12]. Most patients received peripheral
blood stem cell (PBSC) grafts (93%). All patients
gave written informed consent for inclusion in the
transplant studies. The transplant protocol was ap-
proved by the national and local ethics committees.Conditioning Regimen and GVHD Prophylaxis
Conditioning regimens were described elsewhere
[13]. Briefly, Flu 150 mg/m2 was combined with Bu8-10 mg/kg (myelogenous malignancies), with mel-
phalan (Mel) 70-140 mg/m2 (multiple myeloma
[MM] and lymphoid malignancies) or with cyclophos-
phamide (Cy) 120 mg/kg (solid tumor), or Cy 120 mg/
kg combined with low-dose total body irradiation
(TBI) 2 Gy (chronic myelogenous leukemia [CML]).
Alemtuzumab (n5 3) or antithymocytic globulin
(ATG) (n5 20) was given as a part of the conditioning
to patients with Hodgkin lymphoma (HL) trans-
planted from unrelated donors and to recipients of
HLA singlemismatch transplants. GVHDprophylaxis
consisted of cyclosporine A (CsA) plus either metho-
trexate (MTX) or mycophenolate mofetil (MMF).
CsA was started on day 27, at a dose of 1 mg/kg 2
times a day inmost patients, and then adjusted to blood
levels (between 200 and 300 mg/mL). MTX was ad-
ministered on days 11, 13, and 16 (10 mg/m2),
with folinic acid rescue being administered within
24 hours after MTX. MMF was instituted on day
0 (at least 10 hours after the infusion of progenitors)
at a dose of 15 mg/kg every 8 hours. MMFwas contin-
ued until day130. Phenytoin prophylaxis was given to
all patients receiving Bu-based conditioning at a start-
ing load dose of 300 mg every 6 hours the day before,
and 300 mg/day until the day after of discontinuation
of Bu. All patients received antimicrobial prophylaxis
with acyclovir, fluconazole, and ciprofloxacin during
the neutropenia and until engraftment.Evaluation and Classification of Neurologic
Complications
A multidisciplinary panel of local neurologists and
hematologists conceived a classification of NC, accord-
ing to the criteria most widely used in studies regarding
allo-HSCT [2,3,5,14,15] (Table 1). Neurology and
hematology specialists retrospectively reviewed all
medical records of patients with neurologic symptoms
after allo-RIC.All patients had been diagnosed by a con-
sultant neurologist either in the hospitalization unit, the
emergency room, or in the outpatient clinic. Because all
the transplanted patients are followed for an unlimited
time in our unit, even if they are also followed in their
original center, late neurologic events were always cap-
tured. If any event occurred outside our institution, we
always contacted the treating physicians to discuss diag-
nosis, management, and eventual referral to our unit.
Management of patients with neurologic events fol-
lowed international clinical guidelines [16-18]. When
pharmacologic toxicity was suspected, treatment was al-
ways discontinued in the case of encephalopathy or neu-
ropathy with severe clinical impairment. Infectious
complications were treated according to the current an-
timicrobial protocol at the unit. To define clinical pre-
sentation, reviewers considered the main neurologic
symptom leading to diagnosis suspicion. This symptom
could develop together with other neurologic or
Table 1. Definition and Diagnosis Classification of Neurologic Complications
Nervous system Definition Diagnosis
CNS
Cerebrovascular Focal encephalopathy and/or headache and/or impairment
of consciousness.
Neuroimaging study suggestive of clinical evidence after
evaluation by neurologist.
Neuroimaging test (CT scan and/or MRI)
Meningoencephalitis Fever or CNS focal/nonfocal encephalopathy.
CSF compatible with infection.
Microbiological evidence or absence of any other possible cause.
Neuroimaging test (CT scan and/or MRI)
CFS biochemical and microbiologic analysis
Encephalopathy CNS manifestation (impairment of consciousness, visual
disturbances, seizures).
Neuroimaging test compatible.
Laboratory findings indicating a toxic or metabolic cause
related to the event.
Neuroimaging test (CT scan and/or MRI)
Laboratory examination
CSF analysis or EEG (depending on clinical presentation)
Idiopathic seizures Clinical evidence of seizures.
Absence of laboratory, Neuroimaging, EEG, or CSF analysis
findings suggesting any other cause.
Neuroimaging test (CT scan and/or MRI)
Laboratory examination
CSF analysis or EEG (depending on clinical presentation)
Other Neurologic event not included in the other categories Depending on clinical presentation
PNS
Mononeuropathy Sensory-motor disturbances suggesting PNS impairment in
a single nerve territory
Electroneurography (according to neurologist criteria)
Polyneuropathy Sensory-motor disturbances suggesting PNS impairment in several
nerves territories
Electroneurography (according to neurologist criteria)
CSF analysis (depending on clinical presentation)
CT indicates computed tomography; MRI, magnetic resonance imaging; CNS, central nervous system; PNS, peripheral nervous system; CSF,
cerebrospinal fluid; EEG, electroencephalogram.
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dromes were considered. Unspecific multifactorial
symptoms such as tremor, mild reversible headache,
and corticosteroid myopathy and/or encephalopathy
in the context of premortem multiorgan failure were
not included in the study. Patients with NC resulting
from neurologic relapse of their malignancies were ex-
cluded from the analysis, but are explained as an aside.Statistical Analysis and Endpoints
The primary endpoint was to describe and classify
NC in the allo-RIC setting. Secondary objectives were
to estimate the incidence of NC and its impact on
overall survival (OS) and NRM, and to identify the
possible risk factors of such complications. OS and
NRMwere defined as the time from day 0 of the trans-
plant to death from any cause and death from any cause
but relapse, respectively. Patients who died or relapsed
before engraftment were not considered evaluable for
acute GVHD (aGVHD) analysis. Patients who died
or relapsed before day 1100 were not considered
evaluable for chronic GVHD (cGVHD) analysis.
The incidences of NC, aGVHD, cGVHD, NRM,
and relapse were calculated using cumulative incidence
estimates, taking into account the competing risks
[19,20]. To analyze the impact of GVHD in the devel-
opment of NC, these variables were entered as time-
dependent covariates. We considered prior relapse as
a competitive event for these items. The probability
of OS was estimated from the time of transplantation
using Kaplan-Meier curves [21] and compared using
the Taron-ware and the Log rank tests. Comparison
between baseline characteristics in patients catego-
rized as with NC and without NC was performedusing 2 2 tables made by means of chi-squared or
Fisher’s exact t-tests. Median times were compared
by means of the Wilcoxon rank sum test. All tests of
significance were 2 sided, with a significance level of
P # .05. All statistical analyses were performed using
SPSS version 15.0 (SPSS, Chicago, IL), with the
exception of the cumulative incidence analyses, which
were carried out with NCSS 2004 (Number Cruncher
Statistical System, Kaysville, UT).RESULTS
Patients’ Characteristics
One hundred ninety-one consecutive adult patients
who received an allo-RIC at the Hospital de la Santa
Creu i Sant Pau were included in this study.Median fol-
low-up for survivors was 48 months (range: 3-98). De-
tailed characteristics of patients are summarized in
Table 2.Incidence, Type of Complications, Etiology,
and Risk Factors
Twenty-seven (14%) patients developed a total of
31 NC. Twenty-three patients had only 1 event,
whereas 4 had 2. Two of the latter 4 patients developed
2 neurologic events affecting CNS and 2 presented 1
CNS and 1 PNS event. Twenty-three (74%) of 31
NC involved the CNS, whereas 8 (26%) involved the
PNS. Twenty-five (81%) of 31 events occurred in
patients receiving immunosuppressive drugs (11 events
with CsA, 6 with CsA and prednisone, 2 with CsA and
MMF, 2 with MMF and prednisone, 2 with prednisone
alone, 1 with MMF and sirolimus, and 1 with MMF
Table 2. Patients’ Characteristics
All Patients (n5 191) Patients with NC (n5 27) Patients without NC (n5 164) P
Median age, years (range) 51 (18-71) 53 (27-68) 50 (18-71) .2
Male sex, n (%) 121 (63) 20 (74) 101 (62) .3
Underlying disease, n (%)
Myeloid 69 (36) 9 (33) 60 (37) .8
Lymphoid 113 (59) 18 (67) 95 (58) .5
Other 9 (5) 0 (0) 9 (6) .4
Donors, n (%)
HLA ident.sibling 157 (82) 19 (70) 138 (84) .1
Alternative donors* 34 (18) 8 (30) 26 (16) .1
Sex mismatch
Female to male, n (%) 51 (27) 9 (33) 42 (26) .5
Prior HSCT, n (%) 74(39) 13 (48) 61 (37) .3
Conditioning regimen, n (%)
Fludarabine-melphalan, 119 (62) 20 (74) 99 (60) .2
Fludarabine-busulfan 61 (32) 6 (22) 55 (34) .3
Other 11 (6) 1 (4) 10 (6) 1.0
GVHD prophylaxis, n (%)
CsA +MTX 134 (70) 19 (70) 115 (70) 1.0
CsA +MMF 52 (27) 8 (30) 44 (27) .8
CsA 3 (2) 0 (0) 3 (2) 1.0
Other 2 (1) 0 (0) 2 (1) 1.0
Graft composition
CD34+ 106/kg, mean (range) 6.3 (1.6-15.6) 6.7 (3.1-15.5) 6.2 (1.6-15.6) .5
CMV serology
D+/Re+, n (%) 123 (64) 17 (63) 106 (65) 1.0
Stem cell source, n (%)
Peripheral blood 178 (93) 27 (100) 151 (92) .2
Bone marrow 13 (7) 0 (0) 13 (8) .2
Ident indicates identical; HSCT, hematopoietic stem cell transplantation; CsA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil; D,
donor; Re, receptor; GVHD, graft-versus-host disease; NC, neurologic complications.
*Alternative donors are referring to unrelated adult donors and HLA mismatched related donors.
1442 Biol Blood Marrow Transplant 15:1439-1446, 2009P. Barba et al.alone). The cumulative incidence of NC at 4 years was
16% (95% confidence interval [CI] 11-23). Cumulative
incidences of CNS and PNS complications were 11%
(95% CI 7-18) and 4% (95% CI 2-10), respectively.
We did not identify any risk factors for the devel-
opment of NC among type of conditioning, type of
donor, GVHD prophylaxis regimen, previous autolo-
gous HSCT, underlying disease or patients’ comor-
bidities (Tables 2 and 4). In the same way, we did
not observe higher incidence of NC in patients with
prior neurovascular events (Table 4). Two patients
with prior neurovascular events developed NC, both
involving the CNS. One of them developed seizures
attributed to severe hypophosphatemia and died 58
days later. The other patient developed PML and
died 87 days later.
CNS Complications
According to the classification used (Table 1), toxic-
metabolic encephalopathy was the main type of CNS
complication in this series (n5 11, 48%) followed by in-
fectious meningoencephalitis (n5 5, 22%) (Table 3).
Drug-related toxicity was directly responsible for 8
(35%) CNS events. One of these was related to Bu and
7 to CsA. Despite the known neurotoxicity of Flu, this
drug was not identified as the primary cause of any of
theNC. Among the other 3 cases of toxic-metabolic en-
cephalopathy, 1 was caused by hypophosphatemia and 1
by hyponatremia. The third case consisted of seizuresduring infusion of rituximab for posttransplant lympho-
proliferative disorder.
Among the cases of infectious meningoencephalitis,
1wasdue toCNSaspergillosis and3werecausedbyviral
infections: 2 herpes simplex (HSV) and 1 adenovirus.
There was an additional case of progressive multifocal
leukoencephalopathy (PML) diagnosed by clinical fea-
tures and magnetic resonance imaging (MRI) findings.
In this case, the JC virus was not isolated.
Regarding cerebrovascular events, 3 were ische-
mic, whereas 1 was hemorrhagic in a patient with arte-
rial hypertension.
PNS Complications
RegardingPNS,5patientsdevelopedamononeurop-
athy and 3 a polyneuropathy (including 1 Guillain-Barre
syndrome). Among mononeuropathies 1 was related to
CsA, 1 to Foscarnet, and 1 to Human Herpes Virus
(HHV) type 6. A well-established cause could not be
identified for the remaining mononeuropathies or for
the polyneuropathies.
Clinical Presentation and Time of Onset
The most frequent presentation (n5 8, 26%) of
NC was a focal syndrome (such as hemiparesis and
dysarthria). Other features were seizures (n5 6) and
peripheral sensory motor disturbances (n5 6), each
in 19% of events. Less frequent clinical pictures were
diffuse high cerebral function disturbance (n5 4,
Table 3. Type, Cause, and Time of Appearance of Neurologic Complications (According to Table 1)
Nervous System n (%) Etiology (n) Time of Appearance Median (Range)
CNS 23 (100)
Cerebrovascular 4 (17) Ischemic (3), Hemorrhagic (1) 242 (154-434)
Meningoencephalitis 5 (22) Viral (4), Fungal (1) 217 (32-1685)
Encephalopathy 11 (48) Toxic (8), Metabolic (3) 25 (0-67)
Idiopathic seizures 2 (9) Unknown (2) 76 (58-94)
Other 1 (4) Unknown (1) 691 (–)
PNS 8 (100)
Mononeuropathy 5 (63) Toxic (2), Unknown (2), Infectious (1) 223 (59-369)
Polyneuropathy 3 (37) Unknown (3) 274 (152-1089)
CNS indicates central nervous system; PNS, peripheral nervous system.
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tions), impairment of consciousness (n5 3, 10%), and
headache (n5 2, 6%).
Median time of onset for NC was 115 days after
transplantation (range: 0-1685). The median time of
appearance for CNS complications was 60 days (range:
0-1685) and 233 days (range: 59-1089) for PNS com-
plications. The presentation of CNS NC was more
often observed in the first 100 days after allo-RIC; 14
of 23 (61%) of them were observed within this period.
In contrast, PNS NC were more delayed, with only 1
of 8 (13%) being observed during this period
(P5 0.01). Of note, 4 (13%) of 31NCwere considered
late events (after 1 year). Of them, 2 affected CNS
(median 1188 days, range: 691-1685) and 2 PNS
(median: 725 days, range: 369-1081).Outcome
GVHD
One hundred eighty-seven (98%) patients were
evaluable for aGVHD assessment. Of these, 101
(54%) developed aGVHD,with a cumulative incidence
of grade II-IV aGVHDof 28% (95%CI 22-35). ThereTable 4. Risk Factors Evaluation
Patients with NC Complications (n5 2
Comorbidities
Creatinine (mmol/L) 98 (54-150)
Smoking 11 (41)
AT 4 (15)
Cardiac failure 3 (11)
Arrhythmia 2 (7)
Alcoholism 0 (0)
Psychiatric disturbance 0 (0)
Diabetes Mellitus 3 (11)
Neurovascular disease 2 (7)
Seizures 1 (4)
TBI-based regimen 1 (4)
CNS radiation (for any reason) 1 (4)
In vivo T cell depletion 5 (19)
Cum. Inc aGVHD I-IV 62% (CI 95%45-83)
Cum. Inc aGVHD II-IV 28% (CI95% 22-35)
Cum.Inc cGVHD 65% (CI95% 47-90)
Cum Inc Ext cGVHD 19% (CI95% 8-46)
Cum. Inc Relapse at 1 year 18% (CI95% 8-41)
NC indicates neurologic complications; Cum. Inc, cumulative incidence; CI, co
GVHD, graft-versus-host disease: aGVHD, acute graft-versus-host disease;
Ext, extended.were no differences in the development of aGVHD
between patients with and without NC (Table 4).
One hundred forty-two (74%) patients were evalu-
able for cGVHD.One hundred (70%) of these patients
developed cGVHDwith a 4-year cumulative incidence
of 72% (95% CI 53-85). There were no statistically
significant differences between those patient who
developed NC and those who did not (Table 4).
NRM
Fifty-three (28%) patients died from NRM after
a median follow-up for the whole group of 19 months
(range: 0.3-99). Median time to death was 118 days
(range: 8-1730). The cumulative incidence of NRM
for the whole group was 29% (95% CI 23-38) at 19
months. The most common causes of NRM were
GVHD and infections (25 patients died from
GVHDwith infection, 17 fromGVHDwithout infec-
tion, and 8 from infection without GVHD). Among
the 27 patients with NC, 15 (56%) (14 CNS and 1
PNS events) died at a median of 79 days (range:
0-533). Six of them (40%) died within the first 30
days after developing CNS NC (3 toxic-metabolic en-
cephalopathies, 2 meningoencephalitis, and 1 vascular7) Patients without NC Complications (n5 164)
91 (55-231) .1
77 (47) .5
37 (23) .7
26 (16) .8
4 (2) .2
19 (12) .08
14 (9) .2
19 (12) 1
6 (4) .3
3 (2) .5
3 (2) .5
11 (7) 1
18 (11) .2
56% (CI 95% 46-61) .4
31% (CI95% 17-55) .7
79% (CI 95% 72-88) .5
27% (CI95% 20-36) .3
28% (CI95% 22-36) .3
nfidence interval; AT, arterial hypertension; TBI, total body irradiation;
cGVHD, chronic graft-versus-host disease; CR, conditioning regimen;
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1444 Biol Blood Marrow Transplant 15:1439-1446, 2009P. Barba et al.hemorrhage). Twelve (44%) of 27 patients remained
alive, 6 with neurologic sequelae. Among them, 2
patients remained with hemiparesis (vascular events),
2 with paresthesia and neuropathic pain (one with
mononeuropathy and 1 with polyneuropathy), 1 with
mild dysphagia (mononeuropathy), and 1 with a pro-
gressive dementia (included in the others category).
The cumulative incidence of NRM at 1 year for
patients who developed NC was 37% (95% CI 22-63)
compared to 20% (95% CI 15-27) for those who did
not (P5 .08). This difference was even higher when
we compared those with CNS involvement, 42%
(95%CI25-71)with thosewithout (PNS complications
and no NC) 20% (95% CI 15-17) (P5 .02) (Figure 1).
Relapse and OS
The cumulative incidence of 1-year relapse was
27% (CI 95% 21-34) for the whole group. There
were no differences in the relapse rate between the 2
groups (Table 4). Of note, all baseline disease CNS
relapses belonged to solid organ malignancies (n5 4).
OS at 4 years was 43%. It was 42% versus 43% for
patient with and without NC, respectively (P5 .4)
(Figure 2). However, OS was lower in patients who
developed CNS complications than in those who did
not (33% versus 45%, P5 .05) (Figure 3).Days after transplant
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Figure 3. OS in patients with/without CNS involvement. a Patients
without CNS NC include patients with PNS complications and patients
without any NC.DISCUSSION
The cumulative incidence of 16% in our series
indicates that NC remain an important clinical issue
after allo-HSCT, even when RIC is used. The impact
of conditioning regimen in the development of NC is
controversial. One study in adults [3] conducted
mainly in patients receiving MA allo-HSCT reported
higher 1-year incidences of NC (cumulative incidence
of 23%) than in our study, and identified the use ofMA
conditioning as a risk factor for CNS complications.
However, other studies in adults [10] and pediatric
patients [2] did not confirm the impact of MA regi-
mens in the development of NC and reported similarincidences to those in the present study. Obviously,
because all of our patients received an allo-RIC, we
could not explore the impact of conditioning regimen
in the development of NC after transplant, but consid-
ering these controversial results we think that it needs
to be further explored in future studies including pa-
tients receiving MA and RIC regimens.
The incidences of CNS and PNS complications in
our study were 11% and 4%, respectively. These values
are slightly higher than in other studies focused on NC
in adult Allo-RIC patients [5,6]. Kishi et al. [6] reported
a cumulative incidence for CNS complications at day
1100 after allo-RIC of 7.8%, but they did not consider
PNS complications or NC occurring beyond day1100
after transplantation. Avivi et al. [5] reported an NC
(CNS and PNS) incidence of 8.9% during the first
year after transplant, in a series of 85 patients who re-
ceived alemtuzumab-based Allo-RIC. Despite the lack
of major differences between these studies and our
own, the slightly higher incidence ofNC in our patients
could be explained by the fact that we included not only
CNS,but alsoPNS involvement, andbecause the longer
follow-up of our study allowed us to identify late
Biol Blood Marrow Transplant 15:1439-1446, 2009 1445Neurological Complications after Allo-RICcomplications in 4 (15%) of the 27patients. Another dif-
ference that could influence the trend toward a higher
NC incidence in our study is that nearly all (.90%) of
our allo-RIC patients received Flu and/or CsA, both
identified as risk factors for NC [22]. This circumstance
did not allow us to analyze the possible impact of the
concomitant use of bothdrugs on theoccurrenceofNC.
In line with prior reports [8,23], the most frequent
causes forNC in our series were toxic-metabolic disor-
ders (13of 31NC, 42%), infections (19%), and vascular
events (13%). CsA was identified as the primary cause
(26% in our study) of NC, as was found by other au-
thors [2]. CsA has a marked neurologic toxicity on
the CNS and the PNS. Clinical manifestations fre-
quently range from postural tremor or palmar pares-
thesias to generalized tonic-clonic seizures or
posterior reversible encephalopathy syndrome. The
mechanisms of CsA neurotoxicity are diverse, and
most of them remain under investigation. One in vitro
model study has suggested that CsAmay induce neuro-
nal apoptosis and selective oligodendrocyte death [24].
Other proposed mechanisms are the induction of is-
chemic disturbances in the brain by endothelial damage
(such as in the thrombotic microangiopathy) and the
interaction with adrenergic receptors on cranial vessels
[25]. The development of CsA-induced hypomagnese-
mia may also contribute to its neurotoxic effects [26].
We did not identify any risk factors for the de-
velopment of NC (Table 4). This could be from
the limited statistical power of the study and the
limited number of patients. Type of transplant, dis-
ease status, MA conditioning, acute myelogenous
malignancy, GVHD greater than grade II, use of
CsA, use of alemtuzumab, female sex, the use of um-
bilical cord blood (UCB) as stem cell source and
TBI as part of conditioning regimen have been sug-
gested as risk factors for NC after allo-HSCT by
several groups [3,14]. Some of these factors, such
as the use of CsA, Flu, or Bu, have well-established
biologic correspondence and have been recognized
as common chemotherapeutic agents that might
cause CNS toxicity [27]. The use of radiation on
the CNS (either in the conditioning regimen for
the allo-RIC [n5 4] or its previous use in those pa-
tients who had received an autologous transplant
[n5 7], or as a treatment for baseline disease before
transplant [n5 1]) did not have any influence on the
development of NC in our series (Table 4). Avivi
et al. [5] observed several PNS complications in
patients treated with alemtuzumab, and suggested
that this drug could be a possible risk factor in the
development of these complications. The proposed
mechanism would be that lymphopenia could faci-
litate viral infections causing radiculoneuropathy
and myelitis. However, we did not find an associ-
ation between TCD cell depletion (TCD; Alemtu-
zumab or ATG) and the development of PNScomplications in our series (PNS complications
appeared in 4.5% of transplants with TCD and in
3% of those without TCD, P5 .5). Further studies
are therefore needed to elucidate the role of TCD
on PNS toxicity in the allo-RIC setting.
Fifteen of the 31 NC (48%) appeared before
day 1100. A group from Canada also identified the
first 100 days posttransplant as a high-risk period for
neurologic events, with 69% of the CNS compli-
cations of their series occurring within this period
[3]. Of note, we also identified lateNC, such as demen-
tia (included in the ‘‘others’’ categories in our classifi-
cation), mononeuropathies, and polyneuropathies.
Some of these events appeared more than 3 years after
transplantation. These and another group’s findings
[14] enhance the importance of longer observation pe-
riods in clinical studies regarding NC after HSCT.
Interestingly, we found that neurologic events
involving CNS appeared earlier (median of 60 days,
0-1685) than those affecting PNS (median of 233
days, range: 59-1089). Because infections, hemor-
rhages, and acute pharmacologic toxicity (the main
causes for CNS complications) appearmore frequently
within the first months after transplantation, the find-
ing is not surprising. In contrast, PNS complications
are usually related to long-term pharmacologic toxicity
or cGVHD.To the best of our knowledge, no previous
data to the reported here gave insights on the median
time to PNS complications in this setting.
As reported in a previous study, NC had a negative
impact on outcome [3]. In this series, a trend to higher
1-year NRM was observed in patients with NC. Of
note, patients with CNS involvement had a signifi-
cantly higher 1-year NRM (42% versus 20%,
P5 .02), reflected in a lower OS (33% versus 45%,
P5 .05). These findings enhance the suggestion that
NC and especially CNS complications constitute an
important cause of mortality after allo-HSCT. It is
of interest that a quarter of the patients in our series
survived the NC, but had clinically significant impair-
ment. In line with other studies, these results empha-
size the negative impact that NC have, not only on
mortality, but also on morbidity and quality of life of
the patients [3,7,15].
In conclusion, the study reported here confirms
that NC have diverse causes and clinical features.
Complications involving the CNS had earlier onset
and more severity than PNS complications.ACKNOWLEDGMENTS
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